In contrast, checkpoint inhibitors like CTLA-4 or PD-L1, which may boost but cannot induce anti-tumor immune responses, are frequently associated with significant adverse events, which can be dose limiting [66]. The gene discussed is CTLA4; the disease is neoplasm.